GlobeNewswire by notified

Forventet udlodning vedrørende regnskabsåret 2023 for børsnoterede afdelinger/andelsklasser i Investeringsforeningen Jyske Invest


Nedenfor har vi angivet de forventede udbyttesatser for foreningens børsnoterede udloddende afdelinger/andelsklasser vedrørende regnskabsåret 2023.

Udlodningen forventes udbetalt ultimo januar 2024 og udbetales dermed inden generalforsamlingens endelige godkendelse.

Det understreges, at de anførte tal alene er foreløbige og således kan ændre sig indtil det endelige årsregnskab foreligger. Den endelige udlodning vedrørende regnskabsåret 2023 skal godkendes på foreningens ordinære generalforsamling i foråret 2024.

De forventede udbyttesatser er beregnet pr. 20. november 2023 og udtrykt i kroner pr. investeringsbevis.

ISINKort navn

Afdelings-/andelsklasses navnForventet udbytte pr. bevis i kr.
DK0010106111 JYIKOB Jyske Invest Korte Obligationer* 0,00
DK0015855332 JYILOB Jyske Invest Lange Obligationer* 0,00
DK0016002652 JYINOB Jyske Invest Nye Obligationsmarkeder* 0,00
DK0060010098 JYINOBV Jyske Invest Nye Obligationsmarkeder Valuta* 0,00
DK0016112915 JYIVIRK Jyske Invest Virksomhedsobligationer* 0,00
DK0060762466 JYIVOSRIKL Jyske Invest Virksomhedsobligationer SRI KL 0,00
DK0060185726 JYIHRV Jyske Invest Højt Ratede Virksomhedsobligationer* 0,00
DK0010106384 JYIOBAKKL Jyske Invest Obligationer og Aktier KL 0,00
DK0061413317 JYIBDA Jyske Invest Bæredygtige Aktier KL 0,00
DK0060512275 JYIALVKL Jyske Invest Aktier Lav Volatilitet KL 0,50
DK0010149863 JYINYAKL Jyske Invest Nye Aktiemarkeder KL 0,00
DK0010240431 JYIFJASRIKL Jyske Invest Fjernøsten Aktier SRI KL 0,00

* = andelsklasse

Øvrig information

Henvendelser vedrørende denne meddelelse kan ske til Senior Director Finn Beck, tlf.
89 89 24 81.

Vedhæftet fil

For at se dette indhold fra, så skal du give din accept på toppen af denne side.
For at se dette indhold fra, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

New wording of AB Akola Group Articles of Association is registered, the name of the company changes and the authorized capital is increased5.12.2023 07:30:00 CET | Press release

On 4 December 2023, a new wording of the Articles of Association of AB Akola Group (hereinafter – “the Company“) was registered in the Register of Legal Entities (enclosed). AB Linas Agro Group has changed name to AB Akola Group. The new wording of the Articles of Association was approved on 27 October 2023 during the Annual General Meeting of Company's Shareholders together with the decision to increase the authorised capital of the Company by EUR 1,764,518.92, issuing 6,084,548 new ordinary registered book-entry shares. The newly issued shares were subscribed for by employees and/or members of the corporate bodies of the Company who had entered into a share option agreement with the Company in 2018 and 2020 and provided the Company with a notice of exercise of the option in 2023. The new shares are granted free of charge, and they are paid by the Company from the reserve set up by the Company for share granting. Additional information: Mažvydas Šileika, CFO of AB Akola Group Mob. +37

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation5.12.2023 07:00:00 CET | Press release

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to pal

Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury5.12.2023 04:41:56 CET | Press release

With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group. Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3. In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition

Nokia comments on AT&T vendor plans5.12.2023 03:30:00 CET | Press release

Nokia Corporation Stock Exchange Release 5 December 2023 at 4:30 EET Nokia comments on AT&T vendor plans Espoo, Finland – Nokia has a wide-ranging relationship with AT&T, supplying products and services across wireless, wireline and other network technologies, alongside similar relationships with other major North American network operators. Nokia is aware of AT&T’s plans to commit to an Open RAN deployment in collaboration with other vendors over the next five years. As a result, Nokia now expects revenue from AT&T in Mobile Networks will decrease over the next 2-3 years. AT&T accounted for 5-8% of Mobile Networks net sales year-to-date in 2023. The already announced action Nokia is taking to reduce its cost base is expected to partially mitigate the impact of AT&T’s decision. Nokia expects Mobile Networks to remain profitable over the coming years but this decision would delay the timeline of achieving double digit operating margin by up to 2 years. Nokia has invested heavily in the

Canadian Government Awards New Funding to General Fusion5.12.2023 02:00:00 CET | Press release

RICHMOND, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion announced that Canada’s Strategic Innovation Fund (SIF) has awarded CA$5 million to support research and development to advance the company’s Magnetized Target Fusion (MTF) demonstration at its Richmond headquarters. Called LM26, this ground-breaking machine will progress major technical milestones required to commercialize zero-carbon fusion power by the early to mid-2030s. The funds are an addition to the existing contribution agreement with SIF, to support the development of General Fusion’s transformational technology. Fusion energy is the ultimate clean energy solution. It is what powers the sun and stars. It’s the process by which two light nuclei merge to form a heavier one, emitting a massive amount of energy. By 2100, the production and export of the Canadian industry’s fusion energy technology could provide up to $1.26 trillion in economic benefits to Canada. Additionally, fusion could completely offset